congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
An open-label, interventional, multicenter study of trastuzumab deruxtecan monotherapy in patients with unresectable and/or metastatic HER2-low or HER2 immunohistochemistry 0 breast cancer: DESTINY-Breast15
Poster
Other/Multi
SABCS 2023 | December 5-9, 2023
Attrition rates from first- to third-line therapy in HER2+ metastatic breast cancer in Europe
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
Blocking soluble TNF to improve potency of trastuzumab deruxtecan by increasing internalization and antitumor innate immune response in a resistant HER2-positive breast cancer model
Poster
Dato-DXd
SABCS 2023 | December 5-9, 2023
Durvalumab + datopotamab deruxtecan in patients with PD-L1–positive
advanced/metastatic triple-negative breast cancer: Arm 8 of the phase 1b/2, open-label, platform BEGONIA study
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
European real-world experience of patients with HER2+ advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: First interim analysis of EUROPA T-DXd
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
Exposure-efficacy and exposure-safety analysis of trastuzumab deruxtecan in patients with advanced/metastatic HER2+ breast cancer: Analyses from phase 3 studies DESTINY-Breast02 and DESTINY-Breast03
Poster
Other/Multi
SABCS 2023 | December 5-9, 2023
Patient characteristics and treatment sequencing among HER2-low metastatic breast cancer patients with rapid vs delayed progression on first-line endocrine therapy
Poster
Other/Multi
SABCS 2023 | December 5-9, 2023
Patient preferences for HR+/HER2- metastatic breast cancer treatments in Italy: A qualitative assessment
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in HER2-positive breast cancer subjects: Analyses across twelve phase 1-3 studies
Páginas:
1 2